• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Joke of a company

Quote
how are they messing up flow. Everyone has TC flow now, heck some companies are even leasing flowcytometers to clients and interpreting the results for pennies per case. How could plus be any worse?
 








They only get clients after donating EMRs and trying to bring pathology in their office. The smart docs leave after the EMR donation because plus is dumb enough not to sign them in a contract. Their science is just another me too lab with nothing to offer.

Why do you think they are losing docs every day to local labs. The management is poor and unethical and they are getting what the deserve!
 




At post 20:
-------------------------
"Hey it is you freaking geniuses that caused the government to cut reimbursement for Urovysion (I know you will blame Bostwick but your just as bad!)

Now you’re trying to fuck-up flow for everyone. What’s next……?""
-------------------------

You are dead on here. Actions by Plus directly led to this cut in re-imbursement.
Give me a break here..you dont think someone who pays for the professional component of a study is going to question paying 200 dollars for an interpretation that takes less than 30 seconds!! It is no wonder payers have cut this to the bone.

Offering FISH as a TC/PC was a monumental FU and looks like a scam to payers, thanks a lot Doug, Edwin etc.

at post 23
--------------------------------
"They only get clients after donating EMRs and trying to bring pathology in their office. The smart docs leave after the EMR donation because plus is dumb enough not to sign them in a contract. Their science is just another me too lab with nothing to offer.

Why do you think they are losing docs every day to local labs. The management is poor and unethical and they are getting what the deserve! "
--------------------------------

Another one dead on (? same poster). Anyways I am aware of a couple of urology groups who squeezed Plus for this donation only to end business with them in less than a yr. Laughing their a$$es all the way to the bank.
 




There seems to be one or 2 posters who are bitter with plus dx. Plus is a 60 Million dollar a year Lab with only a handful of clients. Do you really think that Plus is responsible for the CMS cut in FISH reimbursement. Bio reference, CBL, Bostwick as well as large physician groups who have set up Histo labs have 10 times as many clients as Plus has in the urology market. Plus is not doing anything that every other isnt already doing. It just becomes an issue when they steal business from competitors. There are major urology groups who have been abusing FISH for years. This was happening before plus ever started
 




Anonymous said:
There seems to be one or 2 posters who are bitter with plus dx. Plus is a 60 Million dollar a year Lab with only a handful of clients. Do you really think that Plus is responsible for the CMS cut in FISH reimbursement. Bio reference, CBL, Bostwick as well as large physician groups who have set up Histo labs have 10 times as many clients as Plus has in the urology market. Plus is not doing anything that every other isnt already doing. It just becomes an issue when they steal business from competitors. There are major urology groups who have been abusing FISH for years. This was happening before plus ever started
Click to expand...

Who was the first to offer FISH as a TCPC test? Was it not PLUS?
 
















Anonymous said:
UROVYSION = PLUS

HemeFish = Neogenomics

IHC = US LABS/Chromovision (now Clarient, no make that GE Healthcare)
Click to expand...

I thought it was plus that was first to offer tc/pc for urine fish test.

So abusive..there is one pathologist who apparently 'interpreted' 150 fish cases in one business day. I guess it is not that hard to count to two a few hundred times a day. No wonder payers arent paying anymore. Again thx a lot plus
 




Lawsuit, Medical Director and questions

I am interviewing with Plus and want to know about the company. Is there still an outstanding lawsuit with Abbott and Plus? Did their Medical Director just quit? I heard their Sales Director is a piece of work, true?
 




"I am interviewing with Plus and want to know about the company. Is there still an outstanding lawsuit with Abbott and Plus?"

No this is now history. Plus lost credibility and some business over this. Abbott sales reps and execs very vocal about this and Abbott has a much better rep in the field (i.e clinicians believe and Abbott rep rather than a Plus rep in a he said she said situation)
Bostwick labs and others did the exact same thing to Plus, only they were smart enough to remove Urovysion from their test reports.

"Did their Medical Director just quit?"

Havent heard this

"I heard their Sales Director is a piece of work, true?"

More like a piece of sh1t

You should read the other strings. Most of the anti-plus stuff is true and easily verified.
 




PLUS as grown 75% annually for the last 5 years and is exploding from a marketshare perspective everyday. In addition to being the fastest growing AP lab in the industry, top reps easily surpass $300k in total compensation. All this while Dianon continues to crumble (all of the good people left for PLUS a while ago), Bostwick is hanging on by a thread, CBL was gobbled up by an Austrialian clinical lab (Sonic), Path Solutions acquired by Aurora (chroic acquirer of labs)...I could go on.

The bottom line is that PLUS is a horrible place to be...
 




Anonymous said:
PLUS as grown 75% annually for the last 5 years and is exploding from a marketshare perspective everyday. In addition to being the fastest growing AP lab in the industry, top reps easily surpass $300k in total compensation. All this while Dianon continues to crumble (all of the good people left for PLUS a while ago), Bostwick is hanging on by a thread, CBL was gobbled up by an Austrialian clinical lab (Sonic), Path Solutions acquired by Aurora (chroic acquirer of labs)...I could go on.

The bottom line is that PLUS is a horrible place to be...
Click to expand...

Ha, ha. Despite this Plus periodically doesnt make payroll, struggles to pay vendors and struggles to reimburse expense accounts. Please explain.
 








Anonymous said:
Fastest growing Lab in the industry...Did GE pay 600 Million for Plus...

I think you need to rethink your comment.

Signed a Wall Street Analyst!
Click to expand...

???? You didnt actually respond, offer any rebuttal or refute the statement of the post you quote.

So again care to explain how a company claiming to be flush with cash cant make payroll. A wall street analyst my a$$. You are a plus suit, not in sales, most likely edwin.
 








Anonymous said:
PLUS as grown 75% annually for the last 5 years and is exploding from a marketshare perspective everyday. In addition to being the fastest growing AP lab in the industry, top reps easily surpass $300k in total compensation. All this while Dianon continues to crumble (all of the good people left for PLUS a while ago), Bostwick is hanging on by a thread, CBL was gobbled up by an Austrialian clinical lab (Sonic), Path Solutions acquired by Aurora (chroic acquirer of labs)...I could go on.

The bottom line is that PLUS is a horrible place to be...
Click to expand...

This is where the WSA got his information. somebody should tell the WSA that most of the posts on these boards have no credibility and are a load of hog-Wash!
 




Listed below are data points relative to PLUS, as published:

- Plus achieved profitability in late 2007 (per CEO Berg in press release Aug 2008)
- Plus is owned by Water Street Capital Partners
- Senior Sales Management came from US Labs which was acquired by LabCorp. US Labs become the oncology hub for all oncology labs LCA purchased to include Dianon and Esoterix. Genzyme is also being gathered under the US Labs umbrella.

It is possible PLUS would sell to a larger company if the price was sufficient, however Water Street Capital Partners have indicated they are interested in purchasing companies as part of their growth strategy.

PLUS is diversified in various markets as compared to other oncology labs:
- Genitourinary Pathology
- Gastrointestinal Pathology
- Hematopathology
- Dermatopathology
- Breast Pathology
- Oral and Maxillofacial Pathology

Anyone who works for or joins a company should evaluate the management team and determine if the culture and leadership style fits their own needs/requirements. No company is perfect. Based on the investments from WSCP and collections from insurance providers, PLUS is not in peril financially.
 




Anonymous said:
Listed below are data points relative to PLUS, as published:

- Plus achieved profitability in late 2007 (per CEO Berg in press release Aug 2008)
- Plus is owned by Water Street Capital Partners
- Senior Sales Management came from US Labs which was acquired by LabCorp. US Labs become the oncology hub for all oncology labs LCA purchased to include Dianon and Esoterix. Genzyme is also being gathered under the US Labs umbrella.

It is possible PLUS would sell to a larger company if the price was sufficient, however Water Street Capital Partners have indicated they are interested in purchasing companies as part of their growth strategy.

PLUS is diversified in various markets as compared to other oncology labs:
- Genitourinary Pathology
- Gastrointestinal Pathology
- Hematopathology
- Dermatopathology
- Breast Pathology
- Oral and Maxillofacial Pathology

Anyone who works for or joins a company should evaluate the management team and determine if the culture and leadership style fits their own needs/requirements. No company is perfect. Based on the investments from WSCP and collections from insurance providers, PLUS is not in peril financially.
Click to expand...

Wow..this will take a few lines.

First of all D Berg is ex-CEO and dishonest. Left the company after a deal in New England including 2 illegal contracts one involving paying urologists for business via an intermediate company blew up costing the company over 100,000 in legal fees and hush money. Probably fired but I suppose it is possible he left on his own.

Lakewood was bought out by Wall Street Capital and now they regret this decision. Lakewood was struggling financially and still continues to struggle. The only difference is they are now called PLUS.

In general all AP speciality labs are struggling, including Bostwick. PLUS is hoping a sucker will come along to buy them out. Extremely unlikely to happen. Local Hospital labs are finally catching up to the speciality labs and offerering split billing etc and recouping lost business. Also urologist and gastroenterologis and local pathologists are building out labs and keeping everything. These trends will be the end of PLUS.

PLUS is not really diverse. Nearly all of their business is prostate biopsies and Urine FISH. A little GI is also present. There is absolutely no breast pathology going to PLUS and very little Heme, Derm or Oral path. Breast pathology is barely a break even endeavor anyways because the time per case is too long (i.e. a pathologist can sign out 12 prostate biopsies in the time it takes them to sign out one breast bx). No reason for PLUS to even go after this business. This is put on their website to distract from what they really are, which is a prostate biopsy factor.

Finally WSCP only invested in this company thinking they could sell for a profit after a few years. They cant and now they are stuck. If you dont think PLUS is in financial straits call anyone at Leica and ask about PLUS's history of non-payment or speak to a current or former employee about the multiple times missing payroll.

Agree with previous posts, that in general take anonymous posts with a grain. But the claims that I make are easily verified, talk to people at national meetings, take an interview. Once you speak with EH, or DP things will start to make more sense.
 




Top Bottom
Back
Quote